Drug Trial News

RSS

AbbVie reports positive results from ABT-494 Phase 2 clinical trials in patients with rheumatoid arthritis

AbbVie, a global biopharmaceutical company, today announced results from two Phase 2 clinical trials evaluating its investigational selective JAK1 inhibitor, ABT-494, in patients with inadequate response to either methotrexate or TNF inhibitors.

25 Sep 2015

Pabetalone (RVX-208) to be tested in proof-of-concept pilot study in complement mediated diseases

Resverlogix Corp. announced today the commencement of an Orphan Disease Program specific for Complement Mediated Diseases. New data generated by Resverlogix has demonstrated that BET inhibition by apabetalone (RVX-208) has effects on multiple biological pathways that underlie disease pathology.

24 Sep 2015

Rhythm Metabolic awarded FDA grant to advance ongoing setmelanotide clinical trial in Prader-Willi syndrome

Rhythm announced today the award of a $1 million research grant from the FDA Office of Orphan Products Development to its subsidiary, Rhythm Metabolic, Inc., to support the ongoing Phase 2 clinical trial of setmelanotide, the company's novel peptide MC4 agonist, for the treatment of obesity and hyperphagia in Prader-Willi syndrome (PWS).

24 Sep 2015

Study raises questions about direct applicability of clinical trial data for cancer drugs

When prescribing newly approved drugs, physicians rely on data from clinical trials to understand the benefits and risks of those drugs for patients. But a study published in the Journal of Oncology Practice showed that for certain cancer drugs, participants in clinical trials are often not representative of the patients that ultimately take the drugs, raising questions about the direct applicability of trial data.

24 Sep 2015

OncoGenex reports results from Phase 2 Rainier study in patients with untreated metastatic pancreatic cancer

OncoGenex Pharmaceuticals, Inc. announced today initial results from the Phase 2 Rainier study evaluating apatorsen in combination with ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) and gemcitabine compared to ABRAXANE and gemcitabine alone in patients with untreated metastatic pancreatic cancer.

23 Sep 2015

FDA approves LONSURF for treatment of patients with metastatic colorectal cancer

Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), today announced that the U.S. Food and Drug Administration approved LONSURF (trifluridine and tipiracil), formerly known as TAS-102, for the treatment of patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy.

22 Sep 2015

AmpliPhi's novel bacteriophage therapy demonstrates comparable efficacy to vancomycin in S. aureus lung infection model

AmpliPhi Biosciences Corporation, a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced experimental results highlighting that its prototype bacteriophage cocktail demonstrated comparable efficacy to vancomycin in reduction of Staphylococcus aureus in a murine lung infection model.

22 Sep 2015

BWH, DFCI researchers receive $10 million to test effectiveness of aspirin in women with breast cancer

Researchers from Brigham and Women's Hospital and Dana-Farber Cancer Institute have received a $10 million Breakthrough Award from the Department of Defense's Office of the Congressionally Directed Medical Research Program to test whether aspirin helps women with breast cancer avoid recurrence and live longer.

22 Sep 2015

Results from phase 3 women-only HIV study show improved safety, efficacy of Stribild drug

Results from the first phase 3 HIV study to enroll only women show improved safety and efficacy of the drug Stribild over multi-pill antiretroviral drug regimens. The research was presented at ASM's 55th Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC/ICC).

21 Sep 2015

Higher doses of hydrocortisone not linked to neurodevelopmental impairments in low birth weight infants

Hydrocortisone is one of the 15 most frequently prescribed medications in extremely low birth weight (?1000 g) infants in the newborn intensive care unit (NICU).

21 Sep 2015

CTCA at Western begins clinical trial that combines immunotherapy with chemotherapy to target sarcomas

Cancer Treatment Centers of America at Western Regional Medical Center in Goodyear, Arizona, has begun Phase II of another arm of its multi-arm clinical trial that combines immunotherapy with chemotherapy.

21 Sep 2015

Genetically engineered vaccine eradicates precancerous cervical lesions

Scientists have used a genetically engineered vaccine to successfully eradicate high-grade precancerous cervical lesions in nearly one-half of women who received the vaccine in a clinical trial. The goal, say the scientists, was to find nonsurgical ways to treat precancerous lesions caused by HPV.

18 Sep 2015

PharmaMar begins phase II 'Basket' trial to evaluate safety, efficacy of PM1183 in advanced solid tumors

PharmaMar announced today the start of a multicenter, international, open-label, exploratory phase II "Basket" trial (NCT02454972) to evaluate the efficacy and safety of the anticancer agent PM1183 (lurbinectedin) in advanced solid tumors.

18 Sep 2015

Benitec Biopharma initiates new site for ongoing Phase 1/2a TT-034 trial for hepatitis C

Benitec Biopharma Limited, a clinical-stage biotechnology company developing innovative therapeutics based on its gene-silencing technology, DNA-directed RNA interference (ddRNAi), is pleased to announce it has initiated a new site for its ongoing Phase 1/2a TT-034 trial at the Methodist Health System Clinical Research Institute in Dallas, Texas.

16 Sep 2015

Bionomics’ BNC210 Phase 1 trial for anxiety and depression meets primary endpoint

Bionomics Limited, a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the treatment of diseases of the central nervous system (CNS) and cancer, today reported positive data from the completed Phase 1 multiple ascending dose, placebo controlled clinical trial of BNC210, an orally administered negative allosteric modulator of the alpha-7 nicotinic acetylcholine receptor (alpha-7 receptor) being developed for the treatment of anxiety and depression.

16 Sep 2015

AstraZeneca presents safety and efficacy data for ExQW at 51st Annual Meeting of EASD

AstraZeneca today announced new analyses of exenatide once weekly (ExQW) demonstrating a favorable gastrointestinal (GI) tolerability profile, including less frequent upper and lower GI adverse events (AE), compared to shorter-acting glucagon-like peptide-1 receptor agonists (GLP-1RA), exenatide twice daily (ExBID) and liraglutide once daily (LiraQD).

16 Sep 2015

Avillion enrolls patients in BFORE Phase III trial to treat chronic myelogenous leukemia

Avillion LLP, a co-developer of late-stage pharmaceutical assets, announces the completion of enrolment in a global Phase III clinical trial called "BFORE," which is designed to assess the effectiveness and safety of BOSULIF (bosutinib) as a first-line treatment for patients with chronic phase Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML).

15 Sep 2015

AgeneBio's HOPE4MCI Phase 3 trial receives support from NIH

AgeneBio, a biopharmaceutical company developing innovative therapeutics for unserved patients battling neurodegeneration, announced today that its HOPE4MCI Phase 3 clinical trial has received support from the National Institutes of Health.

15 Sep 2015

UT Southwestern evaluates allopurinol drug to prevent nephropathy in Type I diabetes patients

UT Southwestern Medical Center has joined an international clinical trial studying whether a drug traditionally used to treat gout can help prevent kidney damage in patients with Type 1 diabetes.

15 Sep 2015

EORTC trial evaluates effectiveness of pembrolizumab in patients with high-risk stage III melanoma

A recently opened double- blind phase III EORTC trial 1325 will prospectively assess whether post-operative adjuvant therapy with pembrolizumab, an anti-PD-1 monoclonal antibody, improves recurrence-free survival as compared to placebo in patients with high-risk stage III melanoma.

15 Sep 2015

Drug Trial News

AbbVie reports positive results from ABT-494 Phase 2 clinical trials in patients with rheumatoid arthritis

Pabetalone (RVX-208) to be tested in proof-of-concept pilot study in complement mediated diseases

Rhythm Metabolic awarded FDA grant to advance ongoing setmelanotide clinical trial in Prader-Willi syndrome

Study raises questions about direct applicability of clinical trial data for cancer drugs

OncoGenex reports results from Phase 2 Rainier study in patients with untreated metastatic pancreatic cancer

FDA approves LONSURF for treatment of patients with metastatic colorectal cancer

AmpliPhi's novel bacteriophage therapy demonstrates comparable efficacy to vancomycin in S. aureus lung infection model

BWH, DFCI researchers receive $10 million to test effectiveness of aspirin in women with breast cancer

Results from phase 3 women-only HIV study show improved safety, efficacy of Stribild drug

Higher doses of hydrocortisone not linked to neurodevelopmental impairments in low birth weight infants

CTCA at Western begins clinical trial that combines immunotherapy with chemotherapy to target sarcomas

Genetically engineered vaccine eradicates precancerous cervical lesions

PharmaMar begins phase II 'Basket' trial to evaluate safety, efficacy of PM1183 in advanced solid tumors

Benitec Biopharma initiates new site for ongoing Phase 1/2a TT-034 trial for hepatitis C

Bionomics’ BNC210 Phase 1 trial for anxiety and depression meets primary endpoint

AstraZeneca presents safety and efficacy data for ExQW at 51st Annual Meeting of EASD

Avillion enrolls patients in BFORE Phase III trial to treat chronic myelogenous leukemia

AgeneBio's HOPE4MCI Phase 3 trial receives support from NIH

UT Southwestern evaluates allopurinol drug to prevent nephropathy in Type I diabetes patients

EORTC trial evaluates effectiveness of pembrolizumab in patients with high-risk stage III melanoma

How innovation in dried blood spot testing is transforming neurological disease monitoring

Unlocking live single-cell functional insights

Fluidics in Modern Healthcare & Medical Device Innovation

Latest News